gestational diabetes mellitus
Conditions
Interventions
Normal pregnant controls:none
gestational diabetes mellitus:none
Sponsors
The Third Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1.Age and Gender: Participants must be between 18 and 45 years of age (the specific age range may be adjusted according to the needs of the study). 2.Diagnosis and Medical History: Pregnant women who have been diagnosed with gestational diabetes mellitus (GDM). No other severe complications or comorbidities, such as severe preeclampsia or diabetic ketoacidosis. 3.Informed Consent: Participants must sign an informed consent form, clearly indicating their understanding and agreement to participate in this study. 4.Baseline Data: Participants must provide detailed medical history, medication history, family history, etc. Baseline blood glucose, haemoglobin A1c, lipid levels, etc., must meet the study requirements.
Exclusion criteria
Exclusion criteria: 1.Diseases and complications: Suffering from other diseases that may affect the study results, such as autoimmune diseases, malignant tumours, etc. Severe complications during pregnancy, such as placenta praevia, placental abruption, etc. 2.Medication: Recent use of drugs that may affect blood sugar or blood lipid levels, such as glucocorticoids, lipid-lowering drugs, etc. Currently participating in other clinical trials or studies that may affect the results of this study. 3.Inability to Cooperate: Unable to undergo regular examinations or provide necessary samples as required by the study. Communication barriers or limited understanding, unable to accurately comprehend and follow study requirements. 4.Ethical and Moral Considerations: The participant or their family members believe that participating in the study may cause discomfort or harm. The participant has already been enrolled in other similar clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SREBP1;silence infrmation regulator,sirtuin,SIRTl;nucleotide binding oligomerization domain-like receptor protein 3, NLRP3;miRNA-128-3p;nuclear factor-erythroid 2-related factor,Nr2;glucose transporters-1,GLUT-1;DiGeorge syndrome critical region 8,DGCR8;reactive oxygen species,ROS; | — |
Countries
China
Contacts
Public ContactHan ning
The Third Affiliated Hospital of Zhengzhou University
Outcome results
None listed